Abstract

  During this last time we have had to learn and investigate this new strain of coronavirus, which not only affects the respiratory tract, but also produces a systemic affection of different organs through diffuse endothellopathy and a severe systemic inflammatory response. In relation to the affection of the central nervous system, there is a direct relationship or neurotropism, through the receptors of the type 2 angiotensin converting enzyme (ACE2). This review tries to explain the neurological relationship and SARS-COV 2.

Keywords: Epidemiology; Neurology; SARS; COVID-19; Embolism Thrombosis

References

1. Zhang G., et al. “Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China”. Journal of Clinical Virology 127 (2020): 104364.
2. Richardson S., et al. “Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area”. Journal of the American Medical Association 20 (2020): 2052-2059.
3. Reportes Epidemiológicos de la Sociedad Chilena de Medicina Intensiva (2020).
4. , et al. “Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor”. Pharmacological Research 14 (2020): 104833.
5. Hoffmann N., et al. “SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor”. Cell 181 (2020): 1-10.
6. Tang X., et al. “On the origin and continuing evolution of SARS-CoV-2”. National Science6 (2020): 1012-1023.
7. Lipworth B., et al. “Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection”. The Journal of Allergy and Clinical Immunology: In Practice6 (2020): 1798-1801.
8. Rizo P., et al. “COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm?”. Basic Research on Cardiology3 (2020): 31.
9. Ranucci M., et al. “The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome”. Journal of Thrombosis and Haemostasis (2020).
10. , et al. “Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19”. Military Medical Research 7 (2020): 19.
11. Yan R., et al. “Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2”. Science 6485 (2020): 1444-1448.
12. Spinato G., et al. “Alterations in Smell or Taste in Mildly Symptomatic Outpatients With SARS-CoV-2 Infection”. Journal of the American Medical Association20 (2020): 2089-2090.
13. Baig A., et al. “Evidence of the COVID-19 Virus Targeting the CNS: TissueDistribution, Host−Virus Interaction, and Proposed Neurotropic mechanism”. ACS Chemical Neuroscience7 (2020): 995-998.
14. Helms J., et al. “Neurologic Features in Severe SARS-CoV-2 Infection”. The New England Journal of Medicine 382 (2020): 2268-2270.
15. Aggarwal G., et al. “Cerebrovascular Disease is Associated with an Increased Disease Severity in Patients with Coronavirus Disease 2019 (COVID-19): A pooled analysis of published literature”. International Journal of Stoke4 (2020): 385-389.
16. Toscano G., et al. “Guillain–Barré Syndrome Associated with SARS-CoV-2”. The New England Journal of Medicine 382 (2020): 2574-2576.
17. Zhao K., et al. “Acute myelitis after SARS-CoV-2 infection: a case report”. medRxiv (2020).
18. Morigushi T., et al. “Meningitis/Encephalitis associated with SARS-coronavirus 2”. International Journal of Infectious Diseases (2020).
19. Poyiadji N., et al. “COVID-19–associated Acute Hemorrhagic Necrotizing Encephalopathy: CT and MRI”. Radiology2 (2020).

Citation

Citation: Gabriel Abudinén Adauy. “COVID-19 and Neurology. A Viewpoint". Acta Scientific Neurology 3.11 (2020): 42-44.

Copyright

Copyright: © 2020 Gabriel Abudinén Adauy. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.